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Characterisation of a mouse tumour cell line with in vitro derived
resistance to verapamil
P.R. Twentyman, K.A. Wright & N.E. Fox
MRC Clinical Oncology and Radiotherapeutics Unit, Hills Road, Cambridge CB2 2QH, UK.
Summary We have established a subline (EMT6/VRP) of the mouse tumour cell line EMT6/P with acquired
resistance to the calcium transport blocker verapamil (VRP). The subline was 4-fold resistant to the cytoxicity
of VRP alone compared with the parent line but of similar sensitivity to adriamycin, vincristine or colchicine.
EMT6/VRP cells growing in 75 jig ml- ' VRP were morphologically different from and larger in diameter than
EMT6/P cells, but these two parameters reverted almost to normal within 3 days of VRP removal, although
resistance was retained. Expression of an mRNA coding for P-glycoprotein was similar in EMT6/VRP and the
parent cell line, although considerable hyperexpression was seen in a multidrug resistant subline, EMT6/
ARI.0. Cellular accumulation of both 3H-daunorubicin and 3H-VRP were greater in EMT6/VRP than in the
parent line. Sensitisation to adriamycin by 3.3 jig ml-' VRP was, however, somewhat reduced in EMT6/VRP
(i.e. to 6.1-fold) compared with the 11-fold sensitisation seen in the parent line. It is clear that resistance to
VRP seen in this cell line occurs via a different mechanism from the resistance to drugs such as adriamycin,
vincristine and colchicine seen in multidrug resistant cell lines.
One approach to the problem ofmultidrug resistance (MDR)
in cancer chemotherapy is the use of agents ('resistance
modifiers') which partially restore drug sensitivity to resistant
cells. The resistance modifier which has been most widely
studied is the calcium transport blocker verapamil (VRP)
(Tsuruo et al., 1981, 1983; Slater et al., 1982; Twentyman et
al., 1986a; Coley et al., 1989a,b). In most studies it has been
found that VRP produces greater sensitisation to drugs in-
volved in MDR (e.g. adriamycin (ADM), vincristine, col-
chicine) in MDR cells than in their sensitive counterparts.
The action of VRP appears to be related to the potent drug
efflux mechanism which prevails in MDR cells, probably
mediated by P-glycoprotein (Tsuruo et al., 1982; Fojo et al.,
1985; Bradley et al., 1988). Recent data have indicated that
VRP is capable of binding to P-glycoprotein and may thus
competitively inhibit the binding of the cytotoxic drugs to the
molecule (Cornwell et al., 1987).
One interesting observation has been that MDR cells are
sometimes more sensitive to VRP alone than their sensitive
counterparts (Twentyman et al., 1986a; Warr et al., 1986,
1988; Cano-Gauci & Riordan, 1987) although this is not
always so. Furthermore, Cano-Gauci and Riordan (1987)
have reported that VRP is, itself, a drug involved in the
MDR phenotype in that MDR hamster cells showed a
greatly reduced ability to accumulate radiolabelled VRP.
Despite this, however, the MDR cells were more effectively
sensitised to ADM by VRP than were the sensitive parent
cells. If VRP is a drug involved in the MDR phenotype, it is
possible that VRP may itself be capable of inducing P-
glycoprotein-mediated MDR.
In order to investigate further the relationship between
VRP sensitivity, the ability of VRP to sensitise cells to
cytotoxic drugs, and its effects on cellular pharmacokinetics,
we have derived in vitro a VRP-resistant subline from the
EMT6 mouse tumour cell line. This paper reports on the
characterisation of this line.
Materials and methods
Cells andmedium
The EMT6 mouse tumour cell line (EMT6/P) and its subline
with in vitro derived resistance to ADM (EMT6/ARI.0) have
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been previously described (Twentyman et al., 1986b; Coley et
al., 1989a,b) and have doubling times of 12 and 14-15 h
respectively. Both lines grow as attached monolayers in plas-
tic tissue culture flasks (Falcon). The medium used is Eagles
MEM with Earle's salts, supplemented with glutamine
(0.5 mM), penicillin (100 U mlh'), streptomycin (100jigml')
and 20% new born calf serum (all Gibco Biocult).
Cultures are incubated at 37°C in an atmosphere of 8%
CO2 + 92% air. Preparation of a single cell suspension is
carried out using a double rinse in 0.1% trypsin in PBS
followed by 15min incubation at 37°C and resuspension in
complete medium.
Derivation of the VRP resistant cell line (EMT6/VRP) was
carried out using step-wise increase in the concentration of
VRP in the growth medium. Flasks of EMT6/P cells were
originally set up with a range of concentrations from 10 to
30 jgml-' of VRP in the medium. It was found that rapid
(essentially normal) growth occurred at 10 and 20jigml-',
and that slow but progressive growth of cells occurred at
30jigml-'. After 10 days the concentration of VRP in the
medium of cells originally exposed to 30jLgml-' was in-
creased to 50 jig ml-'. This was further increased to
75jigml-' after an additional 7 weeks, and after a total
period of 12 weeks, progressive growth in a concentration of
75jigml-' VRP was achieved. Increasing the concentration
of VRP beyond 75 jig ml-' has not been possible while main-
taining progressive cell growth, a dose of 100jig ml-I leading
to rapid deterioration and death of the cell population.
Hence the resistant line EMT6/VRP was established as a
frozen stock and has been maintained in culture at this
concentration of VRP (75 jg ml-').
Drugs
Adriamycin (ADM, Farmitalia), and vincristine (Eli Lilly)
were dissolved in sterile water at 500jigml-' and stored at
-20C. Colchicine (Sigma) was dissolved in sterile water at
I mgml-' and stored at - 20°C. Dilutions of these drugs for
use in experiments were made in phosphate buffered saline
(PBS) immediately before use. Verapamil (VRP, Cordilox,
Abbott Laboratories) was obtained as an aqueous solution at
2.5 mg ml-'. This was stored at 4°C and the appropriate
dilution was made in PBS immediately before use in ex-
periments.
Sensitivity testing
The sensitivity of cell lines to cytotoxic drugs alone, VRP
alone or agents in combination was assessed using the MTT
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colorimetric assay (Mosmann, 1983). The assay has been
modified by us and its use with EMT6 cells has been pre-
viously described (Twentyman & Luscombe, 1987). Briefly,
single cell suspensions were prepared from exponential cul-
tures and inoculated into wells on 96-well tissue culture
plates (Falcon) at between 600 and 1,000 cells per well in a
volume of 2001il of medium. Drugs were added to the wells
in volumes of 10-20pl after a period of 2 h incubation to
allow attachment of the cells to the surface of the wells.
Where resistance modifiers and cytotoxics were added to the
same well, an additional period of 1 h was left between
addition of the two drugs. Wells were then incubated at 37°C
for 3 days with the drugs continuously present. MTT (3-4,5
dimethylthiazol-2,5 diphenyl tetrazolium bromide, Sigma)
(20Al of a 5 mg ml-' solution in PBS) was then added to
each well and the plates were returned to the incubator for a
further 4 h. The bulk of the medium was then aspirated from
each well and 200gll of DMSO added. After 5 min agitation
on a plate shaker, plates were read at a wavelength of
540nm (and at a reference wavelength of 690nm) on a
Titertek Multiskan MCC plate reader. In all experiments,
four replicate wells were used to determine each response
point.
Cell size and DNA distribution
The distributions of DNA content of EMT6/P and EMT6/
VRP cells were determined using flow cytometry. Cells from
exponential cultures were resuspended at 5 x 105 ml-' in me-
dium and a volume of 0.125 ml of ethidium bromide/Triton
X solution in water (Taylor, 1980) was added to I ml of cell
suspension. The cells were then run through the Cambridge
flow cytometer (Watson, 1980) using an argon laser oper-
ating at 488 nm. DNA content per nucleus was measured on
the basis of the fluorescence output from each nucleus.
Size distributions were determined on cell suspension di-
luted in 'Isoton' (Coulter) and analysed using a Coulter ZBI
particle counter.
Isotope uptakes
Tritium-labelled VRP hydrochloride (3H-VRP)
(60 Ci mmol-') and tritium-labelled daunorubicin (an ADM
analogue) (3H-DNR) (4.2 Ci mmol-') were obtained from
New England Nuclear. Labelled DNR was used in these
experiments in common with many previous studies, because
of its greater availability compared to labelled ADM. Cells
were inoculated into wells on six-well multiplates (3 cm di-
ameter, Sterilin Ltd) 48 h before experiments. Initial numbers
of cells per well were adjusted so that equal numbers of cells
per well would be present at the time of the experiments, and
these were 4 x 104 per well for EMT6/P; 5 x 104 per well for
EMT6/ARI.0 and 6 x 104 per well for EMT6/VRP. The
latter two cell types were grown in the absence of drug over
this 48 h period. To commence experiments, the medium was
aspirated from each well and replaced with 2 ml of medium
at 37°C containing the labelled compound (0.1IlCi ml-') plus
unlabelled compound to give a final concentration of
0.5 igml-' or 0.4 tgmlm' for VRP or DNR respectively.
After the appropriate incubation time, the medium was again
aspirated from each well and the cells were rinsed three times
with ice cold PBS. One ml of distilled water was then added
to each well and the wells were left for 2 h for cell lysis to
occur. At the end of this time, the contents of each well were
pipetted several times and 0.5 ml transferred to a glass scintil-
lation vial containing 10 ml of Aquasol (New England Nu-
clear). The vials were counted the following day on a Nuclear
Chicago Isocap liquid scintillation counter. A cell count was
carried out on three replicate wells containing each cell type
used in the isotope uptake experiments and set up at the
same time. This allowed the values of uptake per well to be
corrected to uptake per cell.
Northern blot analysis
Cells in the exponential phase of growth were collected by
centrifugation at 300g for 10 min and suspended in 100,sl of
medium. A solution containing 6.0 M guanidine hydroch-
loride and 0.2M sodium acetate (pH 5.5) was added to the
cells (20 ml per 5 x I07 cells) and the DNA was sheared by
vigorous homogenisation in a Virtis homogeniser (Virtis
Company, New York). RNA was precipitated by the addi-
tion of a half volume of 95% ethanol followed by incubation
at - 20°C overnight. The pelleted precipitate was dissolved in
a solution containing 7.0 M urea, 0.35 M NaCl, 50 mM Tris,
pH 7.5, 1 mm EDTA and 0.2% SDS and was extracted once
with phenol-chloroform. RNA was precipitated from the
aqueous phase using 2 volumes of ethanol, washed with 70%
ethanol, air dried and dissolved in sterile double distilled
water.
Twentyltg of total cellular RNA in 1OmM sodium phos-
phate buffer (pH 7.0) was denatured in 1.0 M glyoxal for 1 h
at 50°C (Thomas, 1980). The RNA was then fractionated by
electrophoresis in a 1.4% agarose gel in 10 mM sodium phos-
phate buffer and was transferred by Northern blotting to
nylon filters (Thomas, 1980). After treatment for 2 min with
ultraviolet light, the nylon filters were baked at 80°C for 2 h
before hybridisation.
The pcDRl.3 proble for the mouse A DRIl gene coding
for P-glycoprotein (Gros et al., 1986) was generously pro-
vided by Dr James M. Croop (Center for Cancer Research,
Massachusetts Institute of Technology, USA). This probe
was 32P-radiolabelled according to Feinberg and Vogelstein
(1984).
The labelled probe, at a concentration of 106 counts min-'
ml-' was hybridised to the filter in I M NaCl, 0.1 M
trisodium citrate (6 x SSC), 5% dextran sulphate, 0.02%
Ficoll, 0.02% bovine serum albumen, 0.02% polyvinyl pyr-
rolidone (Denhardt, 1966), 0.1% SDS and 50 tgml1'
sonicated salmon sperm DNA at 65°C for 18h. The filter
was washed with 0.1 x SSC, 0.1% SDS at 65°C to remove
unhybridised probe before autoradiography.
Results
Sensitivity to VRP
The sensitivities of EMT6/P, EMT6/VRP and EMT6/AR1.0
cells to VRP are shown in Figure 1. Similar experiments were
carried out on 12 independent occasions and ID50 values
were determined (ID50 = dose of VRP to reduce final optical
density to 50% of control). Mean ID50 values (standard
error) were EMT6/P = 22.8 (1.8) figml-'; EMT6/VRP = 87.6
(5.4) jig ml-l; EMT6/AR1.0 = 29.5 (2.1) tsg ml-'. Hence the
resistance factors (RF = ID50 of resistant line/ID50 for parent
line) were 3.8 for EMT6/VRP and 1.3 for EMT6/AR1.0.
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Figure I Response to VRP of parent cell line EMT6/P (0),
multidrug resistance subline EMT6/ARI.0 (0) and VRP resistant
subline EMT6/VRP (A). Optical density in the MTT assay has
previously been shown to be proportional to final cell number.VERAPAMIL RESISTANT CELL LINE 281
In three experiments, the RF was determined in parallel
for the EMT6/VRP line maintained in VRP and for the cells
after a period of growth in the absence of the selecting drug.
The results are shown in Table I. It may be seen that,
although the resistance level of EMT6/VRP does change
during subculture, this is independent of the presence or
absence of VRP. More complete reversion studies are cur-
rently in progress.
Sensitivity to cytotoxic drugs
The sensitivities of the three cell types to ADM are shown in
Figure 2. Whereas EMT6/AR1.0 are highly resistant to
ADM (approximately 50-fold), the sensitivity of EMT6/VRP
cells is the same as that of the parent line. Similar data (not
shown) were obtained for sensitivity to vincristine and to
colchicine.
Morphology, growth rate, size and DNA distribution
EMT6/VRP cells showed a distinct morphological change
from the parent cell line (Figure 3). This change occurred
gradually as the dose of VRP was increased. The EMT6/
VRP cells (Figure 3b) have a much rounder shape, a more
granular appearance and a more distinct nucleus than
EMT6/P (Figure 3a). After 3 days growth in the absence of
VRP, however, the appearance of EMT6/VRP cells had
almost reverted to normal (Figure 3c). Whereas the doubling
time of the EMT6/VRP cells maintained in VRP was con-
siderably greater than that of the parent line (17 vs 12 h) the
doubling time returned to 12 h immediately following
removal of VRP.
EMT6/VRP cells growing in the presence of the VRP were
significantly larger in volume than cells of the parent line
(Figure 4). After 3 days growth in the absence of VRP,
however, the size of the EMT6/VRP cells had reverted to
normal. The DNA distributions obtained by flow cytometry
of EMT6/VRP cells growing both in the presence or absence
of VRP were unchanged from the distribution given by
EMT6/P cells (data not shown).
Table I Maintenance of VRP resistance
ID50for VRP (jugml-')
(RFb in parentheses)
Time out of VRP
for EMT6/VRP' EMT6/P EMT6/VRP EMT6/VRP a
OC 23 (1.0) 88 (3.8) -
6 days 16 (1.0) 74 (4.6) 64 (4.0)
2 weeks 38 (1.0) 105 (2.8) 80 (2.1)
6 weeks 23 (1.0) 46 (2.0) 46 (2.0)
aEMT6/VRP cells grown in the absence of VRP.
ID50(resistant line)
bRF (resistance factor) = I (parent line)
'Mean values for 12 determinations (see Results section). The
remaining data shown are from three separate experiments (i.e.
EMT6/VRP cells removed from VRP on three separate occasions).
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Figure 2 Response to ADM of parent cell line EMT6/P (0), P-glycoprotein expression
multidrug resistant subline EMT6/ARl.0 (0) and VRP resistant
subline EMT6/VRP (A). Similar results were obtained for the The expression of the k DRII gene which codes for P-
response of the three lines of vincristine or colchicine. glycoprotein was determined by Northern blot analysis and
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Figure 4 Coulter sizing ofcells following trypsinisation of exper-
imental phase cultures. CONT = EMT6/P cells. VRP + = EMT6/
VRP growing in 75 3Hg ml-' VRP. VRP - = EMT6/VRP after 3 l days growth without VRP.
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the data are shown in Figure 5. The low level of gene b b
expression in the EMT6/VRP line was similar to that seen in
the EMT6/P parent line. This is in contrast to the con-
siderable hyperexpression seen in EMT6IARI.O.
Accumulation of co-VRP and H-DNR
3
The results of experiments to determine the accumulation of
labelled VRP and labelled DNR by EMT6/P, EMT6/ARI .0
and EMT6/VRP cells are shown in Figure 6 and Table II.
Accumulation of 'H-VRP by EMT6/VRP was increased X
compared with EMT6/P whereas that by EMT6/ARI.0 was
slightly (but not significantly) decreased. Accumulation of 2
'H-DNR was also increased (by 2-3-fold) in EMT6/VRP
L
compared with EMT6/P whereas that by EMT6/ARI.0 was
only 20% of control.E
A B C
Time (min)
Figure 6 Cellular accumulation of a 3H-DNR and b 3H-VRP by
parent cell line EMT6/P (0), multidrug resistant subline EMT6/
ARl.0 (0) and VRP resistant subline EMT6/VRP (A). Points
are mean values from three separate dishes. Individual dishes give
values within 10% of the mean.
4 P-glycoprotein
Table 1I Cellular accumulation of 'H-VRP and 3H-DNR
Accumulation per cell as % of
controla
Cell line 3H-VRP 3H-DRN
EMT6/P 100 100
EMT6/VRP 180 (32) 270 (31 )
EMT6/ARI.0 80 (11) 21 (1.2)
aDetermined at 1 h. Values given are means of four separate
experiments with three dishes per point. Standard errors are in
: 11Ill#0l itilillXlMilililililil11S: parentheses.
Figure 5 Northern blot analysis of mRNA prepared from cell Sensitisation to ADM
lines and probed for the mouse ADR1I (P-glycoprotein) gene.
Track A, cell line EMT6/VRP. Track B, cell line EMT6/ARI.0. The ability of VRP to sensitise EMT6/P, EMT6/VRP and
Track C, cell line EMT6/P. EMT6/ARI.0 cells to ADM was tested in six experiments.VERAPAMIL RESISTANT CELL LINE 283
The data are shown in Table III. The EMT6/P line is
unusual in that more sensitisation to ADM by 3.3 lag ml-'
VRP is seen in the parent line than in the MDR line EMT6/
ARlO. (Coley et al., 1989a). The sensitisation seen in line
EMT6/VRP was significantly reduced compared with that in
the parent line from which it was derived.
Discussion
A VRP resistant subline of the mouse tumour cell line
EMT6/P has been produced by growth of cells in increasing
concentrations of VRP over a period of 12 weeks. The
resistance is maintained during a period of growth in the
absence of the inducing agent. Although the cells are larger
and have a different morphology while in the presence of
VRP, these changes are lost within 3 days of removal of the
inducing agent. It is clear from the data presented here that
the mechanism of resistance to VRP is not the same as the
MDR mechanism pertaining in the EMT6/ARI.0 line. The
EMT6/VRP cells are not cross-resistant to ADM, vincristine
or colchicine and they do not hyperexpress P-glycoprotein.
Whereas the EMT6/ARI.0 show the typical reduced accumu-
lation of 3H-DNR seen in MDR lines, the accumulation of
3H-DNR is greatly increased in EMT6/VRP. This result may
reflect to some extent the increased volume of the EMT6/
VRP cells. However, an increase in mean diameter from 13.5
to 15.5jim would provide only a 50% increase in volume, i.e.
much less than the increased accumulation and, in any case,
partial or complete reversion to normal volume would have
occurred during 2 days growth in drug-free medium. The
increased accumulation of 3H-DNR does not, however,
reflect a greatly increased sensitivity to drugs of the MDR
type, as the sensitivity to ADM, vincristine and colchicine of
the EMT6/VRP cells is similar to that of the parent. We have
not examined the sensitivity of the cells to DNR cytotoxicity.
A more comprehensive study of the relationship between
sensitivity and drug accumulation for a range of cytotoxics in
the EMT6/VRP cell line is clearly indicated.
Table III Sensitisation to ADM by VRP
ID50for ADM (jigml-')
EMT6/P EMT6/VRP EMT6/ARI.0
ADM alone 0.076 0.067 3.0
(0.014) (0.023) (0.37)
ADM 0.0070 0.010 0.44
+ 3.3igml-' VRP (0.0010) (0.002) (0.16)
Sensitisation 11.0 6.lb 8.8
ratioa (0.9) (1.2) (1.5)
aSensitisation ratio D50-VRP
ID50 + VRP
bp = 0.006 compared with EMT6/P (2-tailed Student's t test). Values
given are means of six determinations with standard errors in
parentheses.
Although the EMT6/VRP cells are relatively resistant to
VRP, they also accumulate more 3H-VRP than the parent
cells. This is in striking contrast to data for 3H-VRP accum-
ulation in MDR cell lines which are VRP hypersensitive
(Cano-Gauci & Riordan, 1987; Warr et al., 1988). In these
two studies, 3H-VRP accumulation was < 10% and 20% of
parent line levels in cells with VRP-hypersensitivity. Addi-
tionally in our EMT6/ARI.0 cell line, which is 50-fold resis-
tant to ADM compared with the EMT6/P parent, there is a
modest resistance to VRP cytotoxicity at the same time as a
small reduction in 3H-VRP accumulation (Reeve et al., 1989).
These results taken together apparently indicate that VRP
sensitivity is inversely proportional to VRP accumulation.
While it is difficult to propose a mechanistic basis for such an
inverse relationship, it is clear that cellular accumulation is
not the main determinant of VRP sensitivity. This is in
contrast to the situation for MDR cell lines where resistance
is almost invariably associated with reduced accumulation of
MDR type drugs (Bradley et al., 1988).
Resistance to VRP alone is accompanied by a small reduc-
tion in the ability of cells to be sensitised to ADM by VRP
(from I 1.0-fold to 6.1-fold). In previous studies (unpublished)
of the sensitisation of EMT6/P cells to ADM at different
VRP doses, we have found that a sensitisation ratio of 8.3 at
3.3 pg ml-' of VRP was reduced to 5.5 at 1.65fig ml' of
VRP. It is clear therefore that a 4-fold reduction in sensitivity
to VRP alone is accompanied by a similar reduction in VRP
sensitisation to ADM produced by a 2-fold reduction in VRP
dose. The biochemical targets for the two processes may
therefore be overlapping but more detailed dose-response
data will be needed to ascertain whether or not they are
identical. Furthermore, as the VRP resistant cells accumulate
more VRP than the parent line, it is clear that intercellular
VRP concentration is not the determining factor for ADM
sensitisation and possibly therefore that an internal domain
of P-glycoprotein is not the relevant site for such sensitisa-
tion.
The above analysis assumes that the accumulation of 3H-
VRP reflects the intracellular concentration of the agent. This
is by analogy to the intracellular accumulation of agents such
as 3H-DNR. If, however, 3H-VRP is being irreversibly
accumulated on the outside of the cell membrane, then analy-
sis of the data becomes more complicated and a variety of
alternative approaches become possible.
We will in the future examine in more detail the location
of bound 3H-VRP in the three cell types described in this
paper. This will include measurement of 3H-VRP binding to
isolated plasma membranes and to TCA-precipitated high
molecular weight material. Such studies should allow further
elucidation of the relationship between VRP sensitivity, VRP
sensitisation to MDR type drugs and the biochemical deter-
minants of the MDR phenotype.
We are grateful to Dr P.H. Rabbitts for carrying out the Northern
blot analysis.
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